NCT00469898View on ClinicalTrials.gov

Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2010

Conditions
Lung Cancer
Interventions
DRUG

Carboplatin

"Carboplatin dosage calculation to be given on day 1, every 21 days:~Carboplatin (mg) = (AUC of 5) x (GFR + 25)~\*up to 6 cycles at physician's discretion"

DRUG

irinotecan hydrochloride

"50 mg/m2 IV on days 1 and 8 every 21 days~Should be infused IV over 30- 90 minutes."

Trial Locations (8)

37205

St. Thomas Health Services, Nashville

37208

MBCCOP - Meharry Medical College - Nashville, Nashville

37404

Memorial Health Care System, Chattanooga

37901

Tennessee Cancer Specialists, Knoxville

38301

West Tennessee Cancer Center at Jackson-Madison County General Hospital, Jackson

42303

Owensboro Medical Health System, Owensboro

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

V52 4

British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT00469898 - Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter